Eplerenone is an aldosterone antagonist.

Eplerenone is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction and clinical evidence of heart failure after recent myocardial infarction.
Active ingredient Pharmaceutical form Package Therapeutic target
  • Eplerenone
  • F.c. Tablets
  • 25mg
  • 50mg
  • Cardiovascular System- B-Blockers

Other products in "International"